Clinical Trial Update: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

View source ↗

Summary

This ClinicalTrials.gov entry outlines a study evaluating a combination approach using hepatic arterial infusion chemotherapy (HAIC), tyrosine kinase inhibitors…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Ze-yang Ding, MD | Conditions: Hepatocellular Carcinoma Non-resectable | Status: RECRUITING